Name: LEXARIA BIOSCIENCE CORP (LEXX) Stock
Brand: LEXARIA BIOSCIENCE CORP
Rating: 5.5 (3 reviews)

LEXX Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: ACCESS Newswire

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

2 months ago - By: ACCESS Newswire

Lexaria Bioscience Corp. Provides Strategic Update

2 months ago - By: Benzinga - Mentions: BOLT SCLX TSHA RVPH ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 months ago - By: ACCESS Newswire

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2 months ago - By: ACCESS Newswire

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

4 months ago - By: ACCESS Newswire

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

4 months ago - By: ACCESS Newswire

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

2 months ago - By: Benzinga - Mentions: MRM KUKE CPOP BIAF ...

Nasdaq Gains 100 Points; US Consumer Sentiment Falls

4 months ago - By: ACCESS Newswire

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

5 months ago - By: ACCESS Newswire

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

6 months ago - By: ACCESS Newswire

Lexaria Attending BIO International Convention

2 months ago - By: ACCESS Newswire

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

7 months ago - By: ACCESS Newswire

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

8 months ago - By: ACCESS Newswire

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

8 months ago - By: ACCESS Newswire

Lexaria's Human GLP-1 Study #5 Begins Dosing

3 months ago - By: ACCESS Newswire

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

4 months ago - By: ACCESS Newswire

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

6 months ago - By: ACCESS Newswire

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

7 months ago - By: ACCESS Newswire

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

9 months ago - By: ACCESS Newswire

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

7 months ago - By: ACCESS Newswire

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

7 months ago - By: ACCESS Newswire

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

9 months ago - By: ACCESS Newswire

LEXARIA BIOSCIENCE CORP (LEXX) Stock News

LEXX Latest News, Press Relases and Analysis

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Provides Strategic Update

12 Health Care Stocks Moving In Thursday's Intraday Session

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Nasdaq Gains 100 Points; US Consumer Sentiment Falls

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Lexaria Attending BIO International Convention

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)